Neuren Pharmaceuticals Limited

Headquarters: Camberwell, VIC, Australia

CEO: Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA

ASX: NEU -12.97%

Market Cap

A$3.13 Billion

AUD as of Jan. 1, 2024

US$2.13 Billion

history Market Cap History

Neuren Pharmaceuticals Limited market capitalization over time

Evolution of Neuren Pharmaceuticals Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Neuren Pharmaceuticals Limited

Detailed Description

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.


"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

Neuren Pharmaceuticals Limited has the following listings and related stock indices.

Stock: ASX: NEU wb_incandescent



697 Burke Road

Suite 201

Camberwell, VIC 3124


Phone: 61 3 9092 0480